Boryung Pharmaceutical Rises 5.19% Amid Uptrend in Vaccine/Diagnostic Reagents/Quarantine Themes (Including Novel Flu, AI)

On the 14th, the vaccine/diagnostic reagent/quarantine (including novel flu, AI, etc.) theme rose 3.25% compared to the previous day, showing strength. Among related stocks, Boryung Pharmaceutical, which is attracting attention, surged 5.19% compared to the previous day. Boryung Pharmaceutical is known as a manufacturer and seller of pharmaceuticals (such as Gelpos and Kanarb).

[Graph] Major stock price changes in the vaccine/diagnostic reagent/quarantine (novel flu, AI, etc.) theme



According to provisional data compiled at 13:48, foreigners are net buying 35,200 shares of Boryung Pharmaceutical.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Boryung Pharmaceutical ranks 3rd in quant financial ranking (out of 43 stocks) by exceeding the theme’s average scores in growth, stability, and profitability. This can be interpreted as Boryung Pharmaceutical having relatively high investment attractiveness compared to other stocks in the theme from a financial perspective.

[Table] Top stocks by financial scores within the theme


※ Quant financial scores are results analyzed by the robo algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an automatic article generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.